TP53 and breast carcinoma: used CRISPR-Cas9 gene editing technology to target knockout of four breast cancer-related tumor suppressor genes (P53, PTEN, RB1, NF1), transforming healthy breast organoids into breast cancer organoids that can be cultured in vitro for a long time.